TIME FOR ACTION: NAVIGATING NEW PILLARS OF CARE IN THE ASSESSMENT AND MANAGEMENT OF CHRONIC KIDNEY DISEASE IN TYPE 2 DIABETES (AS-110)

Saturday, October 28, 2023

12:30 – 13:30 EST

Location: Palais, 517D

Target Audience: Cardiologists, Endocrinologists, Diabetologists, Internists, Family Physicians, Residents, Allied Health Professionals

Chair : AS(s)

Navdeep Tangri

Attending Nephrologist
Seven Oaks General Hospital
University of Manitoba

Presenter : AS(s)

Marisa Battistella (she/her/hers)

Pharmacy Clinician Scientist
University Health Network- University of Toronto
University of Toronto
Jeffrey Habert

Family Physician
Shops on Steeles Medical Centre
University of Toronto
SM

Sola Mansour (she/her/hers)

Endocrinologist
University of Alberta, Division of Endocrinology and Metabolism
University of Alberta, Department of Medicine, Division of Endocrinology and Metabolism
Sara Stafford (she/her/hers)

Endocrinologist
Fraser Health Authority
University of British Columbia
Shelley Zieroth, MD

Heart Failure Cardiologist, Past President CHFS
St. Boniface Hospital
University of Manitoba

Disclosure(s):

Navdeep Tangri: AstraZeneca: Consultant/Advisory Board (Ongoing); Bayer: Consultant/Advisory Board (Ongoing); Boehringer Ingelheim: Consultant/Advisory Board (Ongoing); CIHR: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); ClinPredict: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing); GSK: Consultant/Advisory Board (Ongoing); Janssen: Consultant/Advisory Board (Ongoing); Kidney Foundation of Canada: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Klinrisk: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing); Marizyme: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing); National Kidney Foundation: Consultant/Advisory Board (Ongoing); NIH: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Otsuka: Consultant/Advisory Board (Ongoing); Prokidney: Consultant/Advisory Board (Ongoing); Quanta: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing); Research MB: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Roche: Consultant/Advisory Board (Ongoing)

Marisa Battistella: Astra Zeneca: Consultant/Advisory Board (Terminated, November 21, 2022), Speaker/Honoraria (Terminated, November 21, 2022); Bayer: Consultant/Advisory Board (Terminated, February 28, 2023); CIHR: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); GSK: Consultant/Advisory Board (Terminated, November 30, 2022); Kidney Foundation Of Canada: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Otsuka: Consultant/Advisory Board (Terminated, April 26, 2023), Speaker/Honoraria (Terminated, April 26, 2023)

Jeffrey Habert: No relevant disclosure to display

Sara Stafford: Abbott: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Astra Zeneca: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Bayer: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); BI: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Dexcom: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Janssen: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Lilly: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Medtronic: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Novo: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); Sanofi: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Tandem: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing)

Shelley Zieroth, MD: Astra Zeneca: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); Bayer: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); BMS: Consultant/Advisory Board (Ongoing); Boehringer Ingelheim: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); Cytokinetics: Consultant/Advisory Board (Ongoing); Eli Lilly: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); GSK: Consultant/Advisory Board (Ongoing); Janssen: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Merck: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); Novartis: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); Novo Nordisk: Consultant/Advisory Board (Ongoing); Otsuka: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Pfizer: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); Roche: Speaker/Honoraria (Ongoing); Servier: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); Vifor: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing)

Learning Objectives / Objectifs d'apprentissage:

At the end of this session participants will be able to / Au terme de cette conférence, vous serez:

articulate the need for action to manage cardiovascular and kidney risk in patients with CKD and T2D;
apply guideline recommendations for the management of patients with T2D and CKD; and
integrate evidence-based, practical treatment approaches for the management of CKD in T2D.

This program was co-developed by the Canadian Society of Endocrinology and Metabolism, Boehringer Ingelheim (Canada) Ltd., Eli Lilly Canada Inc. and Bayer Inc. and was planned to achieve scientific integrity, objectivity, and balance.